Kim Vettenranta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6479688/publications.pdf

Version: 2024-02-01

32	572	840776	677142
papers	citations	11 h-index	22 g-index

37	37	37	909
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. Journal of Clinical Oncology, 2021, 39, 295-307.	1.6	163
2	Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort. Journal of Allergy and Clinical Immunology, 2022, 149, 1744-1754.e8.	2.9	51
3	Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?â€"A multicenter EBMT-PDWP study. Bone Marrow Transplantation, 2020, 55, 1540-1551.	2.4	42
4	Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. Journal of Clinical Oncology, 2021, 39, 2552-2563.	1.6	42
5	Three-Dimensional Echocardiography and Cardiac Magnetic Resonance Imaging in the Screening of Long-Term Survivors of Childhood Cancer After Cardiotoxic Therapy. American Journal of Cardiology, 2014, 113, 1886-1892.	1.6	30
6	RhoG deficiency abrogates cytotoxicity of human lymphocytes and causes hemophagocytic lymphohistiocytosis. Blood, 2021, 137, 2033-2045.	1.4	27
7	Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2020, 55, 1126-1136.	2.4	23
8	Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Frontiers in Pediatrics, 2021, 9, 705179.	1.9	22
9	Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children. , 2000, 34, 319-327.		19
10	Long-Term Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1939-1948.	2.0	19
11	Pediatric acute graftâ€versusâ€host disease prophylaxis and treatment: surveyed realâ€life approach reveals dissimilarities compared to published recommendations. Transplant International, 2020, 33, 762-772.	1.6	19
12	Somatic late effects in 5â€year survivors of neuroblastoma: a populationâ€based cohort study within the Adult Life after Childhood Cancer in Scandinavia study. International Journal of Cancer, 2018, 143, 3083-3096.	5.1	15
13	Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?. Frontiers in Pediatrics, 2021, 9, 784024.	1.9	13
14	Preterm birth, neonatal therapies and the risk of childhood cancer. International Journal of Cancer, 2021, 148, 2139-2147.	5.1	12
15	Cardiac Function After Cardiotoxic Treatments for Childhood Cancerâ€"Left Ventricular Longitudinal Strain in Screening. Frontiers in Cardiovascular Medicine, 2021, 8, 715953.	2.4	10
16	Viremic co-infections in children with allogeneic haematopoietic stem cell transplantation are predominated by human polyomaviruses. Infectious Diseases, 2017, 49, 35-41.	2.8	9
17	Neurologic disorders in long-term survivors of neuroblastoma â€“ a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) research program. Acta OncolÃ³gica, 2020, 59, 134-140.	1.8	8
18	Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens. Pediatric Hematology and Oncology, 2020, 37, 355-364.	0.8	8

#	Article	IF	Citations
19	Adenine Nucleotide Catabolism in the Human Trophoblast Early and Late in Gestation. Pediatric Research, 1988, 24, 373-379.	2.3	7
20	RSV infection complicating the therapy of pediatric malignancies: Report of six cases. , 1996, 26, 261-263.		7
21	Adoptive immunotherapy as consolidation of remission in pediatric AML relapsing post-transplant. Pediatric Transplantation, 2003, 7, 446-449.	1.0	7
22	Polyomaviruses <scp>BK</scp>,<scp> JC</scp>,<scp> KI</scp>,<scp> WU</scp>,<scp> MC</scp>, and <scp>TS</scp> in children with allogeneic hematopoietic stem cell transplantation. Pediatric Transplantation, 2016, 20, 424-431.	1.0	6
23	Maternal autoimmune disease is not associated with cancer in the offspring. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 2259-2266.	1.5	4
24	What Is the Role of HSCT in Philadelphia-Chromosomeâ€“Positive and Philadelphia-Chromosomeâ€“Like ALL in the Tyrosine Kinase Inhibitor Era?. Frontiers in Pediatrics, 2021, 9, 807002.	1.9	2
25	Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection. Cancer Reports, 0, , .	1.4	2
26	Design of a Cytotoxic Neuroblastoma-Targeting Agent Using an Enzyme Acting on Polysialic Acid Fused to a Toxin. Molecular Cancer Therapeutics, 2021, 20, 1996-2007.	4.1	1
27	Intensive Chemotherapy for High-Risk ALL in Children - the Nordic Collaborative Approach. Blood, 2019, 134, 742-742.	1.4	1
28	Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2022, 57, 705-711.	2.4	1
29	Characteristics of white blood cell count in acute lymphoblastic leukemia: A COST LEGEND phenotypeâ€“genotype study. Pediatric Blood and Cancer, 2022, 69, e29582.	1.5	1
30	Acute Lymphoblastic Leukemia with â€œNormalâ€•Karyotype is not without Genomic Aberrations.. Blood, 2008, 112, 1491-1491.	1.4	0
31	Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor Acute Lymphoblastic Leukemia in a Multi-Center Setting. Blood, 2019, 134, 2755-2755.	1.4	0
32	Risk factors in the HR-NBL-1/SIOPEN study in patients receiving dinutuximab beta (DB) based immunotherapy.. Journal of Clinical Oncology, 2020, 38, 10536-10536.	1.6	0